No abstract available.

No abstract available.
Growth Hormone* ; Yeasts*

No abstract available.
Growth Hormone* ; Yeasts*

No abstract available.
Child* ; Growth Hormone* ; Humans ; Pharmacokinetics* ; Yeasts*

No abstract available.

No abstract available.

No abstract available.
Congenital Hypothyroidism*

PURPOSE:The clinical course in adult autoimmune thyroiditis varies: both transient and intermittent hypothyroidism occur during the course of disease and spontaneous recoveries from the hypothyroid state has been described. To determine whether these kinds of variations occur in the course of juvenile chronic lymphocytic thyroiditis and whether the size of thyroid gland, or immunologic measurement such as thyroid antibodies correlated with the course or outcome of juvenile chronic lymphocytic thyroiditis. METHODS:Fifty six patients (54 girls) who attended the clinic between 1986 and 1996 were followed during 36 months prospectively. The clinical diagnosis of juvenile chronic lymphocytic thyroiditis was confirmed by Fisher et al.(1975) criteria in all patients. Assessment of thyroid function was based on clinical diagnosis and on the levels of thyroid stimulating hormone and free thyroxine. Physical examination, thyroid function test and antithyroid antibody test were evaluated with 6 months intervals. RESULTS:Initially, 27 patients were euthyroid, 19 compensatory hypothyroidism and 10 overt hypothyroidism. At the end of follow up, 31 patients were euthyroid, 11 compensatory hypothyroidism and 14 overt hypothyroidism. On one or more occasions, 92.7% of the patients had positive results for thyroid antibodies. Overt hypothyroidism at the end of follow up correlated with the initial thyroid states and with detection of thyroglobulin antibodies. CONCLUSIONS:The best predictors of the final hypothyroid state were initial hypothyroidism and detection of thyroglobulin antibodies.
Adult ; Antibodies ; Diagnosis ; Follow-Up Studies ; Hashimoto Disease* ; Humans ; Hypothyroidism ; Physical Examination ; Prospective Studies ; Thyroglobulin ; Thyroid Function Tests ; Thyroid Gland ; Thyroiditis, Autoimmune ; Thyrotropin ; Thyroxine

Sine the success of human growth hormone (GH) synthesis by DNA recombinant technology, these GH products are widely used in the treatment of children with growth hormone deficiency. Recently, methionyl-GH has been produced in the yeast, Saccaromyces cerevisiae 2150, by the use of a DNA recombinant method in Korea. The purpose of this study was to investigate the clinical efficacy, side effect and immunogenicity of this GH product during therapy of 3year in 22 children with naive GH deficiency. The subjects of this study are aged 4.5~17.9 years, diagnosed by the failure of plasma GH to respond to insulin induced hypoglycemia, arginine and/or clonidine loading and height below -2 standard deviation of mean for their chronological age. Each subjcct received GH 0.45IU/kg/week, intramusculary in 3 devided dose, During treatment, vital signs, height and body weight checked before and every 3 months. Blood count urinalysis, blood chemistry, bone age and measurement of thyroid hormone were performed before, every 3months in year 1, and every 6 months in year 2 and 3. Assay of antibody against GH were performed before, year 1,2 and 3. The height velocity was significantly increased from an average baseline level of 2.9+/-1.1cm/year to 7.9+/-1.9cm/year after the first year, 6.6+/-1.1cm/year during the second year, and 5.9+/-1.2cm/year during the third year of GH treatment. The height standard deviation score for chronological age was decreased from an average baseline of 3.5+/-1.3 to 2.9 1.2 after the first year, 2.7 +/-1.1 during the second year, and 2.5+/-1.2 during the year of GH treatment. The increment in height age was significantly increased from an average baseline of 0.6+/-0.2 year to 1.3+/-0.3 year in year 1, 1.1+/-0.3 year in year 2, and 1.0+/-0.2 year in year 3. The increment in bone age was significantly increased from an average baseline of 0.6+/-0.2 year to 1.2+/-0.2 in year 1, 1.3+/-0.3 year in year , 2, and 1.1+/-0.3 year in year 3. Antibody against hGH was observed in 3 of the 22 patients(13.5%) in year 1 and 1 and in 2 of the 17 patients(17.7%) in year 3. And unwanted side effects were not observed in any of the 22 patients. These results suggest that this yeast derived recombinant methionyl growth hormone appears to be a safe very effective product for treating of children with GH deficiency.
Arginine ; Body Weight ; Chemistry ; Child* ; Clonidine ; DNA ; Growth Hormone* ; Human Growth Hormone ; Humans ; Hypoglycemia ; Insulin ; Korea ; Plasma ; Thyroid Gland ; Urinalysis ; Vital Signs ; Yeasts*

No abstract available.
Humans ; Infant ; Infant Mortality*